Pancreatic Cancer Research

ResearcherChang Gung UniversityActive in the last 2 years

Tai‐Jan Chiu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3978-4167; OpenAlex author ID A5022533478, A5152116890. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 5 papers · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 5 papers

Papers 21

  1. Drastic muscle wasting following surgery is a strong predictor of prognosis in early-stage pancreatic cancer-a Taiwanese multicenter cohort study. Co-author DOI 10.1016/j.ctarc.2026.101468↗
  2. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). Co-author DOI 10.1016/j.ejca.2026.116229↗
  3. Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jfma.2026.01.057↗
  4. Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort. Co-author DOI 10.1016/j.jfma.2026.04.039↗
  5. Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort… Co-author DOI 10.1016/j.jfma.2026.05.008↗
  6. The efficacy and safety profile of third-line treatment in patients with metastatic pancreatic adenocarcinoma. First author DOI 10.1016/j.pan.2025.01.012↗
  7. Validation of a Prognostic Nomogram for Patients with Metastatic Pancreatic Cancer Treated with Nanoliposomal Irinotecan as Second-Line Therapy. First author DOI 10.1177/10732748251333040↗
  8. Outcomes of Liposomal Irinotecan With 5-FU and Leucovorin in Patients With Metastatic Pancreatic Cancer and Borderline Performance Status. First author DOI 10.21873/cdp.10430↗
  9. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Co-author DOI 10.1016/j.bj.2023.100696↗
  10. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.03.014↗
  11. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers15041008↗
  12. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovo… Co-author DOI 10.1002/jhbp.1128↗
  13. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Co-author DOI 10.3389/fonc.2022.800842↗
  14. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Co-author PMID 35530292↗
  15. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma rec… Co-author PMID 36225629↗
  16. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic duc… Co-author PMID 36504882↗
  17. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. Co-author DOI 10.1177/17588359211058255↗
  18. Downregulation of Notch3 links TIMP3 inhibition to suppress aggressive phenotypes of pancreatic ductal adenocarcinoma. Co-author PMID 34873483↗
  19. Inactivation of APC Induces CD34 Upregulation to Promote Epithelial-Mesenchymal Transition and Cancer Stem Cell Traits in Pancreatic Cancer. First author DOI 10.3390/ijms21124473↗
  20. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. Co-author DOI 10.7150/thno.36830↗
  21. Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine. Co-author DOI 10.1186/s12943-015-0449-3↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wen‐Chi Chou · 15 shared papers, 2021–2026 · strength 2.98
  2. Jen‐Shi Chen · 13 shared papers, 2021–2026 · strength 2.37
  3. Li‐Yuan Bai · 12 shared papers, 2021–2026 · strength 2.00
  4. Chung‐Pin Li · 12 shared papers, 2021–2026 · strength 2.00
  5. Yen‐Yang Chen · 12 shared papers, 2021–2026 · strength 1.92
  6. Yung‐Yeh Su · 11 shared papers, 2021–2026 · strength 1.87
  7. Shih‐Hung Yang · 11 shared papers, 2021–2026 · strength 1.75
  8. Nai‐Jung Chiang · 10 shared papers, 2021–2026 · strength 1.50
  9. Yan‐Shen Shan · 11 shared papers, 2015–2026 · strength 1.46
  10. Li‐Tzong Chen · 9 shared papers, 2019–2026 · strength 1.27
  11. Cheng‐Ming Peng · 8 shared papers, 2021–2024 · strength 1.06
  12. Yu‐Shin Hung · 3 shared papers, 2025–2026 · strength 0.91
  13. I‐Wei Ho · 3 shared papers, 2026 · strength 0.75
  14. Chieh-Ying Chang · 2 shared papers, 2025–2026 · strength 0.62
  15. Chi-Chen Lan · 2 shared papers, 2025–2026 · strength 0.54
  16. Hsiu-Tzu Wang · 2 shared papers, 2026 · strength 0.50
  17. Ying‐Jui Chao · 2 shared papers, 2019–2026 · strength 0.36
  18. Yan-Shen Shan · 1 shared paper, 2026 · strength 0.27
  19. Chien-Yu Chen · 1 shared paper, 2026 · strength 0.27
  20. Kun‐Ming Rau · 1 shared paper, 2026 · strength 0.25
  21. Yao‐Yu Hsieh · 1 shared paper, 2026 · strength 0.25
  22. Hsin‐Chen Lin · 1 shared paper, 2024 · strength 0.19
  23. Chien‐Jui Huang · 1 shared paper, 2024 · strength 0.19
  24. Cheng‐Yu Tang · 1 shared paper, 2024 · strength 0.17
  25. Ya‐Chin Hou · 2 shared papers, 2015–2019 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.